Friday, July 10, 2026
🇺🇸 FDA

pharma · Myelodysplastic Syndromes (MDS) · Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)

Taiho Pharma Canada

Taiho Pharma Netherlands B.V.

Taiho Pharma Canada trial registry — 16 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
2010 Winston Park Drive, Suite 503, Oakville, Ontario L6H 5R7, CA HQ
2017 Founded
13 Employees
EMA registrant Type
Company details
Status
Public
HQ
2010 Winston Park Drive, Suite 503, Oakville, Ontario L6H 5R7, CA
Founded
2017
Employees
13
Programs
16
Drugs
30
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Trials

Taiho Pharma Canada clinical trials

Registry index of 16 ClinicalTrials.gov studies linked to Taiho Pharma Canada programs — each row shows trial ID, program name, phase, status, and indication.

Taiho Pharma Canada trial registry — 16 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for Taiho Pharma Canada.

  1. TAS0612-101 — Phase 1

    Clinical update

  2. TAS-120-203 — Phase 2

    Clinical update

  3. ASTX727-18 — Phase 1

    Clinical update

  4. ASTX727-17 — Phase 1

    Clinical update

  5. TAS6417-301 — Phase 3

    Clinical update

  6. TAS-120-206 — Phase 2

    Clinical update

  7. TAS6417-302 — Phase 3

    Clinical update

  8. ASTX727-07 — Phase 2

    Clinical update

Trial registry

16 studies
  9. 2024-516293-29-01

    ASTX727

    Phase 2 active small_molecule

    Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) or solid tumors

    CTIS ↗
  12. 2024-516679-33-00

    Tolinapant, Tolinapant

    Phase 2 active small_molecule

    Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: Cohort#1:Recurrent/metastatic head and neck squamous cell carcinoma; #2:Relapsed/refractory diffuse large B-cell lymphoma; #3:Progressive, refractory or relapsed peripheral T-cell lymphoma; #4:Relapsed/refractory cutaneous T-cell lymphoma; #5: Other tumor types that may have sensitivity to ASTX660; # 6: Cervical carcinoma not responsive/relapsed after standard therapy

    CTIS ↗

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.